KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Capital Leases for 3 consecutive years, with $55.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Leases fell 15.51% year-over-year to $55.7 million, compared with a TTM value of $55.7 million through Sep 2025, down 15.51%, and an annual FY2024 reading of $58.6 million, down 22.42% over the prior year.
  • Capital Leases was $55.7 million for Q3 2025 at Aurinia Pharmaceuticals, down from $59.3 million in the prior quarter.
  • Across five years, Capital Leases topped out at $79.4 million in Q2 2023 and bottomed at $55.7 million in Q3 2025.
  • Average Capital Leases over 3 years is $65.6 million, with a median of $65.4 million recorded in 2024.
  • Peak annual rise in Capital Leases hit 8.64% in 2024, while the deepest fall reached 22.42% in 2024.
  • Year by year, Capital Leases stood at $75.5 million in 2023, then dropped by 22.42% to $58.6 million in 2024, then fell by 4.83% to $55.7 million in 2025.
  • Business Quant data shows Capital Leases for AUPH at $55.7 million in Q3 2025, $59.3 million in Q2 2025, and $56.8 million in Q1 2025.